What physicians need patients to understand about cannabidiol products ...

A medically formulated THC and CBD treatment reduced agitation in a blinded trial involving people with late-stage dementia.

Read more about how standardized outcome measures and design parameters impact Fragile X Syndrome clinical trials in a new ...

Research suggests cannabis suppresses REM sleep, raising questions about memory, emotion and the purpose of dreams.

Jazz Pharmaceuticals JAZZ is best known for its market-leading oxybate franchise, but the company has also carved out a ...

In the phase 2 LiBBY trial presented, tetrahydrocannabinol and cannabidiol reduced agitation scores and improved clinician-rated outcomes in patients with advanced dementia.

Review Article Now Published in the British Journal of Clinical Pharmacology Finds Widely Sold Non-Prescription CBD Products at Doses ...

Texas will ban delta-8, delta-10, THCP and other hemp products July 31. Here's what remains legal after the Supreme Court ...

The adult epilepsy market across the 7MM is poised to grow at a CAGR of 4.4% from $11.4bn in 2025 to $17.8bn in 2035.

Former acting DHS Secretary Chad Wolf urges Congress to investigate Chinese-linked actors' role in THC hemp products and illegal marijuana operations.

In a first-of-its-kind clinical trial, U.S. researchers found that people with agitation and dementia in late life who took a ...

Nearly 90% of trial participants improved with treatment ...